Eran Elinav heads a multi-disciplinary research group of over 30 immunologists, microbiologists, metabolic experts and computational biologists at the Department of Immunology, Weizmann Institute of Science. His lab focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition. The Elinav lab employs diverse state of the art experimental, genomic and computational methods to study the involvement of gut microbes in diverse multi-factorial diseases including obesity and its metabolic complications, inflammatory and autoimmune disorders, neurodegenerative disease and cancer, with an aim to develop microbiome-targeting personalized treatment modalities for these disorders. Dr. Elinav has published more than 130 publications in leading pear-reviewed journals, and received several awards for his discoveries including the Claire and Emmanuel G. Rosenblatt award from the American Physicians for Medicine (2011), the Alon Foundation award (2013), the 2015 Rappaport prize for biomedical research, awarded annually to a single scientist for breakthrough biomedical discoveries, the 2016 Lindner award, Israel society of endocrinology’s highest prize, and the 2016 the Levinson award for basic science research (2016). Since 2016 he is a senior fellow at the Canadian Institute For Advanced Research (CIFAR), and since 2017 he is a Bill & Melinda Gates Foundation & Howard Hughes Medical Institute (HHMI) investigator. Education: Prof. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem summa cum laude, followed by a clinical internship, residency in internal medicine, and a clinical and research position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine.